HematologyNews.net

Hematology Xagena

XagenaNewsletter
Medical Meeting
Xagena Mappa
Gastrobase.it

Search results for "Gazyva"

The first results from CLL11, a phase III study of the investigational medicine Obinutuzumab ( GA101; Gazyva ) were presented. The CLL11 study compared the combination of either GA101 or Rituximab ( M ...


Several new, targeted therapies show promise to expand treatment options for chronic lymphocytic leukemia ( CLL ) and are more effective and better tolerated than standard chemotherapy, according to s ...


The monoclonal anti-CD20 antibody Rituximab ( MabThera, Rituxan ), combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients with previously untreate ...


The results from the pivotal phase III GALLIUM trial in people with previously untreated follicular lymphoma, the most common type of indolent ( slow-growing ) non-Hodgkin lymphoma ( iNHL ), were anno ...


Data from the CLL14 trial, the first randomized clinical trial to examine stopping an oral-based, chemotherapy-free combination after 12 months in previously untreated patients with chronic lymphocyti ...


Researchers have evaluated early disease progression and its impact on overall survival ( OS ) in previously untreated follicular lymphoma patients in GALLIUM, and investigated the effect on early dis ...


Immunochemotherapy is standard of care for patients with previously untreated advanced stage follicular lymphoma ( FL ). Four-year data from the phase III GALLIUM study have previously demonstrated ...


The treatment of relapsed or refractory diffuse large B-cell lymphoma ( R/R DLBCL ) remains challenging. Atezolizumab ( Tecentriq ) and Obinutuzumab ( Gazyvaro ) are monoclonal antibodies acting res ...


Immunochemotherapy is standard of care for patients with previously untreated advanced stage follicular lymphoma ( FL ). Four-year data from the phase III GALLIUM study have previously demonstrated ...